Abstract
SUMMARY: Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
Abbreviations
- FDA
- US Food and Drug Administration
- FSE
- fast spin-echo
- Copyright © American Society of Neuroradiology
